Skip to Content

Daliresp

Active Substance: roflumilast
Common Name: roflumilast
ATC Code: R03DX07
Marketing Authorisation Holder: AstraZeneca AB
Active Substance: roflumilast
Status: Withdrawn
Authorisation Date: 2011-02-28
Therapeutic Area: Pulmonary Disease, Chronic Obstructive
Pharmacotherapeutic Group: Drugs for obstructive airway diseases

Therapeutic Indication

Daliresp is indicated for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add-on to bronchodilator treatment.

The marketing authorisation for Daliresp has been withdrawn at the request of the marketing authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide